← back to search

Ephraim P. Hochberg

University of Alabama at Birmingham · US
🔎 Find collaborators in Pathology and Forensic Medicine · Genetics →
Search 5.9M scientists by topic, h-index, country & funding — free.
Area of research
Pathology and Forensic Medicine · Genetics
Research interest
Research interests include Medicine, Lymphoma, Hodgkin lymphoma, Fludarabine, Hazard ratio, and Chimeric antigen receptor.
h-index
citations
1,837
works
22
NIH funding
primary concept
email

Recent publications

Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy
Blood 2025cited by 9position: middledoi
Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL
Blood Advances 2024cited by 9position: middledoi
Toxicities and outcome after <scp>CD19</scp>‐directed chimeric antigen receptor T‐cell therapy for secondary neurolymphomatosis
American Journal of Hematology 2024cited by 7position: middledoi
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells
Neuro-Oncology 2023cited by 38position: middledoi
NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022
Journal of the National Comprehensive Cancer Network 2022cited by 78position: middledoi
Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network 2020cited by 149position: middledoi
Fatal neurotoxicity after chimeric antigen receptor T-cell therapy: An unexpected case of fludarabine-associated progressive leukoencephalopathy
European Journal of Cancer 2020cited by 13position: middledoi
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells
Blood 2019cited by 342position: middledoi
Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial
The Lancet Haematology 2019cited by 72position: middledoi
Potentially Avoidable Hospital Readmissions in Patients With Advanced Cancer
Journal of Oncology Practice 2019cited by 42position: middledoi
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018
Journal of the National Comprehensive Cancer Network 2018cited by 63position: middledoi
Symptoms of posttraumatic stress disorder among hospitalized patients with cancer
Cancer 2018cited by 44position: middledoi
Use of Antidepressant Medications Moderates the Relationship Between Depressive Symptoms and Hospital Length of Stay in Patients with Advanced Cancer
The Oncologist 2018cited by 15position: middledoi
The relationship between physical and psychological symptoms and health care utilization in hospitalized patients with advanced cancer
Cancer 2017cited by 235position: middledoi
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network 2017cited by 141position: middledoi
A B Cell Regulome Links Notch to Downstream Oncogenic Pathways in Small B Cell Lymphomas
Cell Reports 2017cited by 85position: middledoi
Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations
Blood 2016cited by 157position: middledoi
Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients
Abdominal Radiology 2016cited by 64position: middledoi
Subgraph augmented non-negative tensor factorization (SANTF) for modeling clinical narrative text
Journal of the American Medical Informatics Association 2015cited by 58position: middledoi
Hodgkin Lymphoma, Version 2.2015
Journal of the National Comprehensive Cancer Network 2015cited by 52position: middledoi
Automatic lymphoma classification with sentence subgraph mining from pathology reports
Journal of the American Medical Informatics Association 2014cited by 65position: middledoi
Hodgkin Lymphoma, Version 2.2012 Featured Updates to the NCCN Guidelines
Journal of the National Comprehensive Cancer Network 2012cited by 99position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Areej El‐Jawahri · Harvard University6 papers (2017–2025)P. Connor Johnson · Broad Institute6 papers (2017–2025)Jeremy S. Abramson · Harvard University5 papers (2016–2025)Jörg Dietrich · Harvard University4 papers (2019–2025)Risa Liang Wong · Center for Cancer Research4 papers (2017–2019)Ryan David Nipp · Anna Needs Neuroblastoma Answers4 papers (2017–2019)Jennifer S. Temel · Harvard University4 papers (2017–2019)Daniel E. Lage · Center for Cancer Research4 papers (2017–2019)Jeffrey A. Barnes · Center for Cancer Research4 papers (2016–2025) · 4 papers (2017–2019)Philipp Karschnia · University Hospital Heidelberg3 papers (2019–2025)William F. Pirl · University of California, San Francisco3 papers (2017–2018)María Martínez-Lage · Mass General Brigham3 papers (2020–2025)Matthew J. Frigault · Broad Institute3 papers (2019–2025)David P. Ryan · University of New England3 papers (2017–2018)Barbara J. Cashavelly · Center for Cancer Research3 papers (2017–2018)Jacob D. Soumerai · Harvard University3 papers (2019–2025)Vicki A. Jackson · Boston University3 papers (2017–2018)Joseph A. Greer · Harvard University3 papers (2017–2018)Ronald W. Takvorian · Center for Cancer Research3 papers (2019–2024)
Looking for a research collaborator?
Search millions of scientists by field, institution, impact, and funding status — see their work, find their email, and reach out directly.
Find collaborators in Pathology and Forensic Medicine · Genetics →